Colonoscopy vs Cologuard: Which Screening Is Right for You?

Colonoscopy and Cologuard both find colorectal cancer early, but they do very different things. Colonoscopy is an invasive procedure that visualizes the entire colon and can remove polyps on the spot. Cologuard is a stool DNA test you do at home every three years, with no prep and no sedation. Neither is definitively better for every patient. The right choice depends on your risk level, your medical history, what a positive result would actually mean for you, and whether you have access to a skilled gastroenterologist.

This explainer draws on peer-reviewed research from four gastroenterologists listed in the Convene directory. Seth Sweetser, MD, at Mayo Clinic published directly on the clinical performance of multitarget stool DNA testing and what happens when a positive result triggers a follow-up colonoscopy. Dayna Early, MD, at Barnes-Jewish Hospital co-authored two versions of the NCCN Colorectal Cancer Screening Guidelines, which set the framework for how physicians compare screening options. Sameer Saini, M.D., at Michigan Medicine conducted meta-analyses on colonoscopy surveillance and endoscopy quality metrics. Juan Carlos Bucobo, M.D., at Stony Brook co-authored the 2025 ASGE Colorectal Cancer Screening Project National Summit statement.

How each test works

Colonoscopy is a same-day procedure. A gastroenterologist guides a flexible camera through your entire colon while you are sedated. Any polyps found during the exam can be removed immediately. The prep the day before (a liquid diet and laxative) is the part most patients dread, and there is a small risk of bleeding or bowel perforation from the procedure itself. A clean colonoscopy at average risk typically means no repeat exam for ten years.

Cologuard analyzes a stool sample for two things: abnormal DNA shed by pre-cancerous or cancerous cells, and blood in the stool. You collect the sample at home, ship it to the lab, and get results in a few weeks. There is no bowel prep, no sedation, and no procedure risk. If the result is positive, you need a diagnostic colonoscopy to find out what is actually there. Cologuard is repeated every three years for average-risk patients with a negative result.

At a glance

What Cologuard detects — and what it misses

Cologuard was designed to detect two main categories of lesion: conventional adenomas, which are the most common polyp type that progresses to cancer, and serrated polyps. That second category matters more than many patients realize.

Serrated polyps, including sessile serrated adenomas, are a distinct precursor pathway to colorectal cancer. Research from Seth Sweetser and colleagues at Mayo Clinic published in Clinical Gastroenterology and Hepatology established that serrated polyps shed cells with specific molecular markers, including abnormal DNA methylation, that can be picked up in stool [2]. Cologuard's test panel specifically includes methylation markers targeting this pathway, which is why it catches lesions that a plain fecal immunochemical test (FIT) would miss.

The trade-off: Cologuard has a higher false positive rate than colonoscopy. In the pivotal clinical trial used for FDA approval, roughly 13% of people without cancer or high-grade dysplasia tested positive on Cologuard. A positive result does not mean you have cancer. It means you need a colonoscopy to find out. For some patients, that means undergoing a colonoscopy they might have scheduled in the first place.

What colonoscopy does that Cologuard cannot

The biggest structural advantage of colonoscopy is that it is both a diagnostic and therapeutic procedure. When your gastroenterologist finds a polyp, they remove it in the same visit. You leave without it. With Cologuard, if the test is positive, you have a colonoscopy next anyway — but at that point it is a diagnostic colonoscopy rather than a screening colonoscopy, and the treatment intent is the same.

Research from Seth Sweetser's group at Mayo Clinic, published in Gastrointestinal Endoscopy, examined what happens when gastroenterologists perform colonoscopy on patients with a known positive Cologuard result [1]. In the study, endoscopists who knew about the positive stool DNA result were more thorough. Their withdrawal time was 19 minutes compared to 13 minutes in the blinded group. Adenoma detection rates were 70% versus 53%. The unblinded group also found proportionally more flat or slightly raised lesions on the right side of the colon — the type most likely to be missed. This suggests that a positive stool DNA test, rather than being a failure of that test, actually primes a higher-quality colonoscopy.

Bowel preparation quality has a real effect on what colonoscopy can find. A study published in Gastrointestinal Endoscopy that involved Dayna Early and colleagues found a per-adenoma miss rate of nearly 48% when bowel prep was inadequate [5]. Among the patients who came back for a repeat procedure, 33.8% had at least one additional adenoma. This is not an indictment of colonoscopy — it underscores that the quality of the procedure matters as much as whether you had it. Access to a high-quality endoscopist is part of what makes colonoscopy effective.

What the guidelines say

The NCCN Colorectal Cancer Screening Guidelines — updated in both 2018 and 2020 by a panel including Dayna Early at Washington University — list multiple acceptable screening modalities for average-risk patients [3, 4]. Both colonoscopy and stool DNA testing appear on the recommended options list. The guidelines do not rank one over the other for average-risk adults. They do specify that patients with elevated risk (personal or family history of colorectal cancer or polyps, inflammatory bowel disease, certain hereditary syndromes) should use colonoscopy, not stool-based tests, as their primary screening method.

The 2025 ASGE Colorectal Cancer Screening Project National Summit, co-authored by Juan Carlos Bucobo at Stony Brook, addressed the current landscape directly [9]. The statement reflects the professional consensus that both test categories are legitimate options, while acknowledging that colonoscopy remains the only screening method that is simultaneously diagnostic and therapeutic.

Screening works — the scale of benefit

The evidence that endoscopic screening reduces colorectal cancer mortality is substantial. A 2012 systematic review and meta-analysis by researchers including Sameer Saini at Michigan Medicine examined five large randomized controlled trials involving 416,159 patients and found that flexible sigmoidoscopy screening reduced colorectal cancer incidence by 18% and mortality by 28% [6]. Among patients who actually completed the recommended screening, those figures rose to 32% for incidence and 50% for mortality. Colonoscopy covers the full colon rather than just the lower portion examined by sigmoidoscopy, so the expected effect is larger, though long-term RCT data for colonoscopy specifically are still accumulating.

Research by Sameer Saini on advanced adenoma recurrence adds relevant context for what happens after a colonoscopy finds something [7]. Patients with a history of adenomas face elevated risk of developing additional advanced adenomas, which is why surveillance intervals — the recommended timing for your next colonoscopy — are shorter if your first exam found significant polyps.

Who is a better candidate for each test

Colonoscopy is typically the right choice if you have any of the following: a personal or family history of colorectal cancer or adenomas, inflammatory bowel disease, symptoms like rectal bleeding or unexplained iron deficiency, or any hereditary syndrome (Lynch syndrome, FAP, and others). In these cases, a stool-based test is not adequate — you need direct visualization.

Cologuard is an option for average-risk adults aged 45 to 85 who prefer to avoid a procedure, cannot tolerate sedation, or face barriers to scheduling a colonoscopy. It is also an option for patients who are at average risk but are reluctant to have a colonoscopy — a test you will actually do is better than a test you skip. Research on why physicians and patients deviate from screening guidelines, including Saini's work on surveillance adherence, points out that the best screening program is one that people complete [8].

One thing to understand: Cologuard does not replace colonoscopy, it delays or avoids it for people with a negative result. A positive Cologuard always leads to colonoscopy. If you have Cologuard annually and test negative for years, you have reduced your cumulative colonoscopy burden. If you test positive even once, colonoscopy follows.

Age and insurance coverage

Medicare covers both options for average-risk adults between 45 and 85. Coverage details vary: colonoscopy is covered as a preventive service, meaning no cost-sharing if no polyps are removed. If polyps are found and removed, cost-sharing rules may apply depending on plan type. Cologuard is covered by Medicare every three years. Private insurance coverage differs by plan. Ask your insurance before scheduling, particularly for Cologuard, where out-of-pocket costs can be substantial without coverage.

Questions to ask your gastroenterologist

• Am I average-risk, or does my personal or family history put me in a higher-risk category that requires colonoscopy specifically?
• If I start with Cologuard and it comes back positive, am I prepared to schedule a colonoscopy right away?
• How many colonoscopies does this practice perform per year, and what is the adenoma detection rate for my gastroenterologist?
• If I have colonoscopy, what surveillance interval should I expect based on what the exam finds?
• Is there any reason I cannot safely have a colonoscopy with sedation?

The bottom line

Colonoscopy and Cologuard are both endorsed for colorectal cancer screening in average-risk adults. Colonoscopy finds and removes polyps in one visit, requires bowel prep and sedation, and is the only appropriate option for high-risk patients. Cologuard is a no-prep at-home test done every three years that works well for average-risk adults who want to avoid a procedure, though a positive result always requires a follow-up colonoscopy. For anyone with elevated risk, symptoms, or a history of polyps, colonoscopy is not optional.